Instead, the presence of the FIP1L1-PDGFRA rearrangement is sufficient for the diagnosis of chronic eosinophilic leukemia in patients with a myeloproliferative neoplasm.
In addition to the chromosome 4 deletion, there are several characteristic clinical and pathologic features of chronic eosinophilic leukemia with PDGFRA rearrangement.
Increased eosinophilic myelocytes and myeloblasts have been interpreted as eosinophilic leukemia,[20,21] and a valuable prognostic grading system has been described by Schooley.
However, no specific karyotypic abnormality has been reported in eosinophilic leukemia.
Chronic myelogenous leukemia Chronic myelomonocytic leukemia Mast cell leukemia Chronic monocytic leukemia Chronic neutrophilic leukemia Chronic eosinophilic leukemia
Most recently, Gleevec was approved in the European Union (EU) for the treatment of patients with the rare life-threatening blood disorders myelodysplastic syndromes/myeloproliferative diseases (MDS/MPD) and hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL).
Gleevec tablets are also indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), certain forms of myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome and/or chronic eosinophilic leukemia (HES/CEL) and aggressive systemic mastocytosis (ASM).
Relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a rapidly progressive blood cancer characterized by the presence of the Philadelphia chromosome * Certain forms of myelodysplastic/myeloproliferative diseases (MDS/MPD), which involve certain blood cells made in the bone marrow * Hypereosinophilic syndrome/chronic eosinophilic leukemia
(HES/CEL), which is characterized by the persistent overproduction of eosinophils, a certain type of white blood cell * Aggressive systemic mastocytosis (ASM), which is marked by the presence of too many mast cells, a certain type of white blood cell.